US 12,377,130 B2
Pharmaceutical composition comprising CCN5 as active ingredient, for preventing or treating retinal diseases
Woo Jin Park, Gwangju (KR); and Aeri Yoon, Gwangju (KR)
Assigned to OLIVES BIOTHERAPEUTICS INC., Gwangju (KR)
Appl. No. 17/054,606
Filed by OLIVES BIOTHERAPEUTICS INC., Gwangju (KR)
PCT Filed May 16, 2019, PCT No. PCT/KR2019/006011
§ 371(c)(1), (2) Date Nov. 11, 2020,
PCT Pub. No. WO2019/221576, PCT Pub. Date Nov. 21, 2019.
Claims priority of application No. 10-2018-0056499 (KR), filed on May 17, 2018.
Prior Publication US 2021/0113660 A1, Apr. 22, 2021
Int. Cl. A61K 38/18 (2006.01); A61K 9/00 (2006.01); A61K 35/28 (2015.01); A61K 35/30 (2015.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 48/00 (2006.01); A61P 27/02 (2006.01); C07K 14/475 (2006.01); C12N 15/86 (2006.01)
CPC A61K 38/18 (2013.01) [A61K 9/0048 (2013.01); A61K 35/28 (2013.01); A61K 35/30 (2013.01); A61K 38/179 (2013.01); A61K 39/3955 (2013.01); A61P 27/02 (2018.01); C07K 14/475 (2013.01); C12N 15/86 (2013.01); A61K 48/00 (2013.01); C12N 2750/14143 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A method for treating a retinal disease of a subject in need thereof, comprising:
a step of administering, to the subject, an effective amount of a pharmaceutical composition comprising an active ingredient selected from the group consisting of:
(a) a CCN5 protein; and
(b) a recombinant viral vector comprising a nucleic acid encoding the CCN5 protein;
wherein the retinal disease is proliferative vitreoretinopathy, diabetic retinopathy, or macular degeneration;
wherein the pharmaceutical composition is administered intravitreally or intraocularly.